About US
Contact us
-
FDA grants orphan drug status for GBT's once-daily therapy to treat sickle cell diseaseThe US Food and Drug Administration (FDA) has granted orphan drug designation for Global Blood Therapeutics' (GBT) once-daily therapy GBT440 to treat patients with sickle cell disease (SCD), an inheri2016/1/5
-
Lixte licenses lead cancer compound to Taipei Medical University for new HCC treatmentUS-based Lixte Biotechnology Holdings has granted an exclusive licence of its lead anti-cancer compound, LB-100, to Taipei Medical University (TMU). The compound will be used to develop new treatment2016/1/5
-
Sanofi Pasteur's dengue vaccine Dengvaxia gets approval in PhilippinesSanofi Pasteur has received marketing approval from the Philippines' Food and Drug Administration for Dengvaxia to prevent all four dengue types in individuals aged from nine to 45 years and living in2016/1/4
-
Bayer and CRISPR to form JV to develop new treatments for serious genetic diseasesBayer has entered an agreement with CRISPR Therapeutics to establish a joint venture (JV) to develop new breakthrough therapeutics for curing blood disorders, blindness and congenital heart disease.2016/1/4
-
CFDA issues Naming Rules for Medical Device Generic NameChina Food and Drug Administration (CFDA) recently issued the Naming Rules for Medical Device Generic Name, which will be implemented as of April 1, 2016.2015/12/31
-
Evonik strengthens its German sitesMore than EUR 400 million invested in 2015 Further large-scale projects in the local market planned for 2016 Engel, Chairman of the Executive Board: "By investing in growth and modernization in Ge2015/12/30
-
Boehringer Ingelheim will hire 400, invest €500M in Vienna biologics operationGermany'sBoehringer Ingelheimhas been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its revenues. After doing deals to bolste2015/12/29
-
GSK's new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog saysGlaxoSmithKline ($GSK) has a new drug that's tailored for patients with a specific type of severeasthma. But according to a nonprofit body that evaluates drugs' prices against their clinical effective2015/12/29
-
GSK adds Bristol-Myers pipeline drugs to challenge Gilead in HIVIt wasn't all that long ago that GlaxoSmithKline ($GSK) was considering a spinoff for its HIV drugs division,ViiV Healthcare. Now, though, the company is hanging on tight to that business--and buildin2015/12/28
-
Merck's Keytruda lines up its survival data for stepped-up battle with BMS' OpdivoThe rivalry is heating up between Merck & Co.'s ($MRK) immuno-oncology drugKeytrudaand its counterpart from Bristol-Myers Squibb ($BMY),Opdivo, in lung cancer. Long expected to dominate, Opdivo ha2015/12/28